Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer

Table 2 Tumor regression responses, median (interquartile range)/n (%)

Variable	PAC group (n = 92)	PC group (n = 200)	Statistic	P value
ycT stage			8.782	0.003
T0-2	25 (27.2)	26 (13.0)
T3-4	67 (72.8)	174 (87.0)
ycN stage			4.556	0.033
N0-1	61 (66.3)	106 (53.0)
N2-3	31 (33.7)	94 (47.0)
ycTNM stage			9.815	0.007
I	20 (21.7)	26 (13.0)
II	40 (43.5)	66 (33.0)
III	32 (34.8)	108 (54.0)
Clinical response			15.081	0.002
Complete response	42 (45.7)	55 (27.5)
Partial response	25 (27.2)	58 (29.0)
Stable disease	21 (22.8)	51 (25.5)
Progression disease	4 (4.3)	36 (18.0)
Objective response	67 (72.8)	113 (56.5)	7.104	0.008
Disease control	88 (95.7)	164 (82.0)	9.934	0.002
T downstage (yes)	85 (92.4)	152 (76.0)	11.074	0.001
Pathological response			28.541	< 0.001
TRG 1a	26 (28.3)	13 (6.5)
TRG 1b	16 (17.4)	42 (21.0)
TRG 2	26 (28.3)	55 (27.5)
TRG 3	24 (26.1)	90 (45.0)
Pathological complete response	26 (28.3)	13 (6.5)	25.785	< 0.001
Major pathological response	42 (45.7)	55 (27.5)	9.359	0.002
Number of positive lymph nodes	0 (0-4)	2 (0-8)	-2.879	0.004
Lymph node metastasis rate, %	0 (0-14)	7 (0-33)	-3.010	0.003
Tumor long diameter, cm	3.0 (2.0-5.0)	4.0 (3.0-6.5)	-3.344	0.001
ypT stage				< 0.001
0	28 (30.4)	14 (7.0)
1a	4 (4.3)	10 (5.0)
1b	7 (7.6)	16 (8.0)
2	11 (12.0)	26 (13.0)
3	31 (33.7)	77 (38.5)
4a	8 (8.7)	38 (19.0)
4b	3 (3.3)	19 (9.5)
ypN stage			10.754	0.029
0	49 (53.3)	72 (36.0)
1	12 (13.0)	37 (18.5)
2	16 (17.4)	37 (18.5)
3a	12 (13.0)	31 (15.5)
3b	3 (3.3)	23 (11.5)
ypTNM stage			13.855	0.001
I	42 (45.7)	48 (24.0)
II	19 (20.7)	58 (29.0)
III	31 (33.7)	94 (47.0)

Percentages may not sum to 100% due to rounding. PAC: Programmed cell death protein-1 inhibitors plus apatinib and chemotherapy; PC: Preoperative chemotherapy; TNM: Tumor node metastasis; TRG: Tumor regression grade.